In addition, it will help come up with an algorithm that will aid clinicians in determining which patients would benefit from and can be safely initiated on an SGLT2 inhibitor for purposes of HF prevention based on the patient’s clinical characteristics and clinical parameters, as evidenced in clinical trials. Here, SLC5A2 is linked to hydrops fetalis.